SCHEMBL30983813

SCHEMBL30983813

COc1ccc(Cl)cc1Cn1c(-c2cccc(Br)c2Cl)nc2c(OC3(C)CC3)ncnc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDCD1 Q15116 2/20 0.34
▸ CD274 Q9NZQ7 2/20 0.34
▸ AKT1 P31749 2/20 0.33
▸ CNR1 P21554 4/20 0.33
▸ ADORA3 P0DMS8 2/20 0.33
▸ PIK3CD O00329 2/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ MC4R P32245 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ NSD2 O96028 1/20 0.32
▸ TSHR P16473 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ CRHR1 P34998 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983814 1.00 PDCD1 (0.34) PDCD1CD274AKT1CNR1ADORA3
SCHEMBL30983843 0.91 PDCD1 (0.36) PDCD1CD274AKT1CNR1ADORA3
SCHEMBL30984006 0.88 CNR1 (0.36) CNR1PIK3CDKDM4E
SCHEMBL30984001 0.87 ADORA3 (0.35) PDCD1CD274AKT1CNR1ADORA3
SCHEMBL30983914 0.86 CNR1 (0.35) CNR1ADORA3PIK3CDCNR2MC4R
SCHEMBL31268895 0.86 PDCD1 (0.36) PDCD1CD274ADORA3PIK3CDTSHR
SCHEMBL30984007 0.86 AKT1 (0.38) AKT1CNR1ADORA3CNR2MC4R
SCHEMBL30983441 0.85 PDCD1 (0.36) PDCD1CD274PIK3CDLMNA
SCHEMBL31269078 0.85 CD274 (0.35) PDCD1CD274CNR1ADORA3PIK3CD
SCHEMBL30983926 0.83 ADORA3 (0.35) PDCD1CD274CNR1ADORA3PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB PDCD1 3112/4885CD274 3235/4885AKT1 1383/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB PDCD1 3112/4885CD274 3235/4885AKT1 1383/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB PDCD1 3112/4885CD274 3235/4885AKT1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback